Table 1.
Comparison of clinicopathologic characteristics of patients with AFP-positive GC and AFP-negative GC.
| Characteristic | AFP-positive (n = 191, %) | AFP-negative (n = 2,127, %) | χ2 | P-value | |
|---|---|---|---|---|---|
| Sex | Male | 125 (65.4%) | 1,262 (59.3%) | 2.725 | 0.099 |
| Female | 66 (34.6%) | 865 (40.7%) | |||
| Age (year) | <60 | 87 (45.5%) | 989 (46.5%) | 0.063 | 0.801 |
| >60 | 104 (54.5%) | 1,138 (53.5%) | |||
| ECOG-PS | 0 | 60 (31.4%) | 718 (33.8%) | 1.139 | 0.566 |
| 1 | 78 (40.8%) | 786 (37.0%) | |||
| 2 | 53 (27.7%) | 623 (29.3%) | |||
| Tumor site | Esophagogastric junction | 43 (22.5%) | 599 (28.2%) | 4.160 | 0.245 |
| Gastric body/fundus | 48 (25.1%) | 437 (20.5%) | |||
| Gastric antrum | 58 (30.4%) | 665 (31.3%) | |||
| Leather stomach | 42 (22.0%) | 426 (20.0%) | |||
| Gastrectomy | Subtotal | 73 (38.2%) | 868 (40.8%) | 0.487 | 0.485 |
| Total | 118 (61.8%) | 1,259 (59.2%) | |||
| Tumor size (cm) | <3 | 100 (52.4%) | 1,053 (49.5%) | 0.681 | 0.409 |
| >=3 | 91 (47.6%) | 1,074 (50.5%) | |||
| CEA (ng/ml) | ≤5 | 72 (40.8%) | 887 (41.7%) | 1.159 | 0.282 |
| >5 | 119 (59.2%) | 1,240 (58.3%) | |||
| CA19-9 (U/ml) | ≤30 | 77 (40.3%) | 894 (42.0%) | 0.212 | 0.645 |
| >30 | 114 (59.7%) | 1,233 (58.0%) | |||
| CA72-4 (U/ml) | ≤6.9 | 86 (45.0%) | 936 (44.0%) | 0.074 | 0.786 |
| >6.9 | 105 (55.0%) | 1,191 (56.0%) | |||
| Pathological differentiation | Highly- Moderately | 90 (47.1%) | 953 (44.8%) | 0.380 | 0.538 |
| Poorly | 101 (52.9%) | 1,174 (55.2%) | |||
| pT stage | T1 | 33 (17.3%) | 317 (14.9%) | 3.160 | 0.368 |
| T2 | 31 (16.2%) | 325 (15.3%) | |||
| T3 | 47 (24.6%) | 455 (21.4%) | |||
| T4 | 80 (41.9%) | 1,030 (48.4%) | |||
| pN stage | N0 | 44 (23.0%) | 680 (32.0%) | 6.511 | 0.010 |
| N+ | 147 (77.0%) | 1,447 (68.0%) | |||
| pTNM stage | I | 31 (16.2%) | 349 (16.4%) | 0.435 | 0.804 |
| II | 65 (34.0%) | 770 (36.2%) | |||
| III | 95 (49.7%) | 1,008 (47.4%) | |||
| Lauren type | Intestinal | 87 (45.6%) | 953 (44.8%) | 0.039 | 0.843 |
| Diffuse-Mixed | 104 (54.4%) | 1,174 (55.2%) | |||
| Venous invasion | Yes | 101 (52.9%) | 888 (41.7%) | 8.876 | 0.003 |
| No | 90 (47.1%) | 1,239 (58.3%) | |||
| Nerve invasion | Yes | 138 (72.3%) | 1,293 (60.8%) | 9.746 | 0.002 |
| No | 53 (27.7%) | 834 (39.2%) | |||
| Ki-67 | <50% | 102 (53.4%) | 1,151 (54.1%) | 0.036 | 0.850 |
| ≥50% | 89 (46.6%) | 976 (45.9%) | |||
| Adjuvant chemotherapy | Yes | 134 (70.2%) | 1,268 (63.3%) | 8.150 | 0.004 |
| No | 57 (29.8%) | 859 (36.7%) | |||
| Liver metastasis | Yes | 89 (46.6%) | 530 (24.9%) | 42.084 | 0.000 |
| No | 102 (53.4%) | 1,597 (75.1%) | |||